A Novel Indicator of CMV Infection after Allo-HCT: Current CMV Reactivation (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #789; 596; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "Using this indicator, we compared the time course of CMVR in patients who did or did not receive letermovir (LTV) prophylaxis (the LTV or no-LTV groups)...3 . To assess the impacts of well-established and potentially underestimated factors on CMV infection after HCT."
Cytomegalovirus Infection • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma
|
|
Shunto Kawamura, M.D. 1; Hideki Nakasone, MD, PhD 1,2; Yuki Honjo, M.D. 1,3; Junko Takeshita, M.D. 1; Yukiko Misaki, M.D. 1; Kosuke Takano, MD 1; Kazuki Yoshimura, M.D. 1; Koki Hashino, M.D. 1; Kaisuke Yamamoto, M.D. 1; Yuya Nakata, M.D. 1; Takuto Ishikawa, MD 1; Akari Matsuoka, M.D. 1; Tomohiro Meno, M.D. 1; Yuhei Nakamura, M.D. 1; Masakatsu Kawamura, M.D. 1; Nozomu Yoshino, M.D. 1; Ayumi Gomyo, M.D. 1; Masaharu Tamaki, MD, PhD 1; Machiko Kusuda, M.D., Ph.D. 1; Shun-ichi Kimura, M.D., Ph.D. 1; Shinichi Kako, M.D., Ph.D. 1; Yoshinobu Kanda, MD, PhD 1
|